TPP1 and brain disorder: This is illustrated by a study published by Vuillemenot et al. [105] describing TPP1 enzyme replacement therapy to treat CLN2, an ultra-rare and rapidly progressing brain disorder that affects an estimated 20 children born in the United States each year.